CRG Partners III L.P.'s Form 4 filing
T2 Biosystems, Inc. (TTOO) · filed Sep 26, 2023
- Accession no.
- 0001209191-23-050592
- Filed
- Sep 26, 2023, 5:15 PM ET
- Trade date
- Sep 22, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $1.31M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| CRG Partners III L.P.CIK 0001637591 | 10% Owner |
| CRG Partners III - Parallel Fund (A) L.P.CIK 0001651357 | 10% Owner |
| CR Group L.P.CIK 0001702352 | 10% Owner |
| CRG Partners III (Cayman) Lev AIV I L.P.CIK 0001767509 | 10% Owner |
| CRG Partners III (Cayman) Unlev AIV I L.P.CIK 0001767510 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2023 | Common Stock | SSaleDisposed | −2,031,313 | $0.2588F1 | −$525,703.8 | 7,507,657 | Indirect | |
| Sep 22, 2023 | Common Stock | SSaleDisposed | −1,264,920 | $0.2588F1 | −$327,361.3 | 4,675,098 | Indirect | |
| Sep 22, 2023 | Common Stock | SSaleDisposed | −406,263 | $0.2588F1 | −$105,140.86 | 1,501,531 | Indirect | |
| Sep 22, 2023 | Common Stock | SSaleDisposed | −1,376,848 | $0.2588F1 | −$356,328.26 | 5,088,781 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.25 to $0.2775, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
Referenced by the price of 4 transactions in Table I.